Prazopress

# Prazopress ## Overview - **Classification**: Alpha-1 adrenergic blocker - **Mechanism**: Selectively blocks postsynaptic alpha-1 adrenergic receptors, causing vasodilation and reduction in peripheral vascular resistance. ## Primary Indications 1. **Hypertension**: To lower elevated blood pressure. 2. **Benign Prostatic Hyperplasia (BPH)**: To improve urine flow and reduce symptoms. 3. **Raynaud's Phenomenon**: To improve blood flow and reduce symptom frequency/severity (off-label). ## Adult Dosing ### Standard Dosing **Hypertension** - **Dose**: Initially **0.5 mg** - **Frequency**: 2-3 times daily - **Route**: Oral - **Titration**: Gradually increase, usual range **6-15 mg/day** in divided doses. - **Maximum**: **20 mg/day** **Benign Prostatic Hyperplasia (BPH)** - **Dose**: Initially **0.5 mg** - **Frequency**: 2-3 times daily - **Route**: Oral - **Titration**: Gradually increase, usual range **2-10 mg/day** in divided doses. - **Maximum**: **20 mg/day** **Raynaud's Phenomenon (Off-label)** - **Dose**: Initially **0.5 mg** - **Frequency**: Once daily at bedtime - **Route**: Oral - **Titration**: Gradually increase to **1-2 mg** 2-3 times daily as tolerated. - **Maximum**: **6-10 mg/day** ### Dose Adjustments - **Renal Impairment**: No specific dose adjustments required. Start with lower doses and titrate carefully. - **Hepatic Impairment**: Initiate with lower doses and monitor closely for adverse effects. - **Elderly Patients**: Start with **0.5 mg** once or twice daily. Titrate slowly due to increased sensitivity to hypotensive effects. ## Pediatric Dosing ### Neonates (0-28 days) - **Use**: Not routinely recommended due to very limited safety/efficacy data. - **Special Notes**: Other agents generally preferred for primary hypertension in this age group. ### Infants (1-12 months) - **Use**: Not routinely recommended. Limited safety/efficacy data available. - **Special Notes**: Consult a pediatric specialist (e.g., cardiologist, nephrologist) if use is considered. ### Children (1-12 years) - **Indication**: Refractory hypertension only, under specialist guidance. - **Dose**: Initially **0.05-0.1 mg/kg/dose** - **Frequency**: Every 6-8 hours - **Route**: Oral - **Maximum**: **0.4 mg/kg/day** or **20 mg/day**, whichever is less. - **Special Notes**: Titrate slowly, monitor closely for hypotension. ### Adolescents (13-18 years) - **Approach**: Generally follows adult dosing guidelines. - **Dose**: Start with **0.5 mg** 2-3 times daily. - **Titration**: Titrate slowly based on response and tolerance. - **Maximum**: **20 mg/day** ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to prazosin or other quinazolines. - **Absolute**: History of micturition syncope. - **Relative**: History of orthostatic hypotension (consider for BPH). ### Common Adverse Effects - **Very Common (>10%)**: Dizziness, headache, drowsiness. - **Common (1-10%)**: Nausea, palpitations, orthostatic hypotension, weakness, fatigue, blurred vision. - **Serious but Rare**: Priapism, first-dose syncope, severe allergic reactions. ### Key Drug Interactions - **Other Antihypertensives (e.g., diuretics, beta-blockers)**: Increased risk of hypotension. Monitor BP closely; consider dose reduction. - **PDE-5 Inhibitors (e.g., sildenafil, tadalafil)**: Potentiated hypotensive effects. Administer with caution, consider lower initial doses of prazosin. - **NSAIDs**: May reduce antihypertensive effect. Monitor blood pressure. ## Monitoring & Follow-up - **Before Treatment**: Baseline blood pressure (BP), heart rate (HR). - **During Treatment**: Monitor BP (standing and sitting) regularly, especially after initial dose and dose increases. - **Clinical Signs**: Watch for dizziness, lightheadedness, or syncope, particularly with first dose or dose titration. ## Clinical Pearls - 💡 **First-dose effect**: Administer initial dose of **0.5 mg** at bedtime to minimize risk of syncope. - 💡 **Titration**: Increase dose slowly (e.g., every 3-7 days) to allow for development of tolerance. - 💡 **Patient Counseling**: Advise patients to avoid rapid position changes to prevent orthostatic hypotension. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.